Synthesis, stereochemistry and SAR of a series of minodronate analogues as RGGT inhibitors

European Journal of Medicinal Chemistry

Volumn 46, Issue 10, 2011, Pages 4820-4826

  Błaewska, Katarzyna M ^a,b   Ni, Feng ^a   Haiges, Ralf ^a   Kashemirov, Boris A ^a   Coxon, Fraser P ^c   Stewart, Charlotte A ^c   Baron, Rudi ^d   Rogers, Michael J ^c   Seabra, Miguel C ^d   Ebetino, Frank H ^e   McKenna, Charles E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b LODZ UNIVERSITY OF TECHNOLOGY   (Poland)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e Warner Chilcott Pharmaceuticals   (Ireland)

Author keywords

Absolute configuration; Bisphosphonates; ee determination; Phosphonocarboxylates; RGGT inhibitors; X ray crystallography

Indexed keywords

2 BROMO 3 (IMIDAZO[1,2 A]PYRIDIN 3 YL) 2 PHOSPHONOPROPANOIC ACID; 2 CHLORO 3 (IMIDAZO[1,2 A]PYRIDIN 3 YL) 2 PHOSPHONOPROPANOIC ACID; 2 FLUORO 3 (IMIDAZO[1,2 A]PYRIDIN 3 YL) 2 PHOSPHONOPROPANOIC ACID; 2 HYDROXY 3 (IMIDAZO[1,2 A]PYRIDIN 3 YL) 2 PHOSPHONOPROPANOIC ACID; 3 (IMIDAZO[1,2 A]PYRIDIN 3 YL) 2 PHOSPHONOPROPANOIC ACID; ALPHA CYCLODEXTRIN; BETA CYCLODEXTRIN; BISPHOSPHONIC ACID DERIVATIVE; ENZYME; GERANYLGERANYL PYROPHOSPHATE; PYRIDINE DERIVATIVE; RAB GERANYLGERANYL TRANSFERASE; RAB11 PROTEIN; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL ACTIVITY; CELL ASSAY; CELL VIABILITY; CHIRALITY; COMPUTER MODEL; CRYSTALLIZATION; DRUG EFFECT; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; ENANTIOMER; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MODIFICATION; ENZYME SUBSTRATE COMPLEX; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTEIN PRENYLATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ALKYL AND ARYL TRANSFERASES; ANIMALS; CELL LINE; CELL SURVIVAL; CRYSTALLOGRAPHY, X-RAY; DIPHOSPHONATES; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MODELS, MOLECULAR; PROTEIN BINDING; STEREOISOMERISM;

EID: 79958711547     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2011.04.063     Document Type: Article

References (28)

1. R.A. Baron, R. Tavare, A.C. Figueiredo, K.M. Blazewska, B.A. Kashemirov, C.E. McKenna, F.H. Ebetino, A. Taylor, M.J. Rogers, F.P. Coxon, and M.C. Seabra Phosphonocarboxylates inhibit the second geranylgeranyl addition by Rab geranylgeranyl transferase J. Biol. Chem. 284 2009 6861 6868
2. C.E. McKenna, B.A. Kashemirov, K.M. Blazewska, I. Mallard-Favier, C.A. Stewart, J. Rojas, M.W. Lundy, F.H. Ebetino, R.A. Baron, J.E. Dunford, M.L. Kirsten, M.C. Seabra, J.L. Bala, M.S. Marma, M.J. Rogers, and F.P. Coxon Synthesis, chiral high performance liquid chromatographic resolution and enantiospecific activity of a potent new geranylgeranyl transferase inhibitor, 2-hydroxy-3-imidazo[1,2-a]pyridin-3-yl-2-phosphonopropionic acid J. Med. Chem. 53 2010 3454 3464
3. F.P. Coxon, M.H. Helfrich, B. Larijani, M. Muzylak, J.E. Dunford, D. Marshall, A.D. McKinnon, S.A. Nesbitt, M.A. Horton, M.C. Seabra, F.H. Ebetino, and M.J. Rogers Identification of a novel phosphonocarboxylate inhibitor of Rab geranylgeranyl transferase that specifically prevents Rab prenylation in osteoclasts and macrophages J. Biol. Chem. 276 2001 48213 48222
4. J.E. Dunford, A.A. Kwaasi, M.J. Rogers, B.L. Barnett, F.H. Ebetino, R.G.G. Russell, U. Oppermann, and K.L. Kavanagh Structure-activity relationships among the nitrogen containing bisphosphonates in clinical use and other analogues: time-dependent inhibition of human farnesyl pyrophosphate synthase J. Med. Chem. 51 2008 2187 2195 (Pubitemid 351503274)
5. M.S. Marma, Z.D. Xia, C. Stewart, F. Coxon, J.E. Dunford, R. Baron, B.A. Kashemirov, F.H. Ebetino, J.T. Triffitt, R.G.G. Russell, and C.E. McKenna Synthesis and biological evaluation of alpha-halogenated bisphosphonate and phosphonocarboxylate analogues of risedronate J. Med. Chem. 50 2007 5967 5975
6. F.P. Coxon, F.H. Ebetino, E.H. Mules, M.C. Seabra, C.E. McKenna, and M.J. Rogers Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo Bone 37 2005 349 358 (Pubitemid 41160493)
7. K.W. Cheng, J.P. Lahad, J.W. Gray, and G.B. Mills Emerging role of RAB GTPases in cancer and human disease Cancer Res. 65 2005 2516 2519 (Pubitemid 40490043)
8. S. Boissier, M. Ferreras, O. Peyruchaud, S. Magnetto, F.H. Ebetino, M. Colombel, P. Delmas, J.-M. Delaisse, and P. Clezardin Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases Cancer Res. 60 2000 2949 2954 (Pubitemid 30395820)
9. A.J. Roelofs, P.A. Hulley, A. Meijer, F.H. Ebetino, R. Graham, G. Russell, and C.M. Shipman Selective inhibition of Rab prenylation by a phosphonocarboxylate analogue of risedronate induces apoptosis, but not S-phase arrest, in human myeloma cells Int. J. Cancer 119 2006 1254 1261 (Pubitemid 44258797)
10. P.G.J. Fournier, F. Dauhine, M.W. Lundy, M.J. Rogers, F.H. Ebetino, and P. Clezardin Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo Cancer Res. 68 2008 8945 8953
11. X.L. Tian, R.U. Jin, A.J. Bredemeyer, E.J. Oates, K.M. Blazewska, C.E. McKenna, and J.C. Mills RAB26 and RAB3D are direct transcriptional targets of MIST1 that regulate exocrine granule maturation Mol. Cell. Biol. 30 2010 1269 1284
12. A.J. Roelofs, A. Boyde, M.W. Lundy, C.E. McKenna, K. Blazewska, S.T. Sun, B.A. Kashemirov, R.G.G. Russell, F.H. Ebetino, M.J. Rogers, and F.P. Coxon Bone mineral affinity influences the distribution of a bisphosphonate and a lower affinity analogue in vivo Bone 44 2009 S430 S431
13. K.T. Tan, E. Guiu-Rozas, R.S. Bon, Z. Guo, C. Delon, S. Wetzel, S. Arndt, K. Alexandrov, H. Waldmann, R.S. Goody, Y.W. Wu, and W. Blankenfeldt Design, synthesis, and characterization of peptide-based Rab geranylgeranyl transferase inhibitors J. Med. Chem. 52 2009 8025 8037
14. Z. Guo, Y.W. Wu, D. Das, C. Delon, J. Cramer, S. Yu, S. Thuns, N. Lupilova, H. Waldmann, L. Brunsveld, R.S. Goody, K. Alexandrov, and W. Blankenfeldt Structures of RabGGTase-substrate/product complexes provide insights into the evolution of protein prenylation EMBO J. 27 2008 2444 2456
15. A preliminary account of part of this work has been presented: K.M. Blazewska, B.A. Kashemirov, C.A. Stewart, F.P. Coxon, R. Baron, M.J. Rogers, M.C. Seabra, F.H. Ebetino, C.E. McKenna. Synthesis and biological studies on desoxy- and -halogenated phosphonocarboxylate analogs of minodronate. 42nd Western Regional Meeting of the American Chemical Society. Las Vegas, NV. September 23-27, 2008.
16. O. Trott, and A.J. Olson Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Biol. 31 2010 455 461
17. P.T. Lang, S.R. Brozell, S. Mukherjee, E.F. Pettersen, E.C. Meng, V. Thomas, R.C. Rizzo, D.A. Case, T.L. James, and I.D. Kuntz DOCK 6: combining techniques to model RNA-small molecule complexes RNA 15 2009 1219 1230
18. S.B. Long, P.J. Casey, and L.S. Beese Reaction path of protein farnesyltransferase at atomic resolution Nature 419 2002 645 650
19. K. Ohno, K. Mori, M. Orita, and M. Takeuchi Computational insights into binding of bisphosphates to farnesyl pyrophosphate synthase Curr. Med. Chem. 18 2011 220 233
20. D. Parker Nmr Determination of enantiomeric purity Chem. Rev. 91 1991 1441 1457
21. J.M. Seco, E. Quinoa, and R. Riguera The assignment of absolute configuration by NMR Chem. Rev. 104 2004 17 117
22. K.M. Blazewska, and T. Gajda Assignment of the absolute configuration of hydroxy- and aminophosphonates by NMR spectroscopy Tetrahedron: Asymmetry 20 2009 1337 1361
23. R. Hulst, R.M. Kellogg, and B.L. Feringa New methodologies for enantiomeric excess (ee) determination based on phosphorus NMR J. Royal Neth. Chem. Soc. 114 1995 115 138
24. K. Blazewska, and T. Gajda (S)-Naproxen (R) and (S)-Ibuprofen (R) chlorides - convenient chemical derivatizing agents for the determination of the enantiomeric excess of hydroxy and aminophosphonates by P-31 NMR Tetrahedron: Asymmetry 13 2002 671 674 (Pubitemid 34597025)
25. L. Berlicki, E. Rudzinska, and P. Kafarski Enantiodifferentiation of aminophosphonic and aminophosphinic acids with alpha- and beta-cyclodextrins Tetrahedron: Asymmetry 14 2003 1535 1539 (Pubitemid 36588853)
26. A.W. Schuttelkopf, and D.M.F. van Aalten PRODRG: a tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr. Sect. D Biol. Crystallogr. 60 2004 1355 1363 (Pubitemid 41079731)
27. L. Almirante, A. Mugnaini, N. De Toma, A. Gamba, W. Murmann, and J. Hidalgo Imidazole derivatives. IV. Synthesis and pharmacologic activity of oxygenated derivatives of imidazo[1,2-a]pyridine J. Med. Chem. 13 1970 1048 1051
28. A. Gueiffier, M. Lhassani, A. Elhakmaoui, R. Snoeck, G. Andrei, O. Chavignon, J.C. Teulade, A. Kerbal, E.M. Essassi, J.C. Debouzy, M. Witvrouw, Y. Blache, J. Balzarini, E. DeClercq, and J.P. Chapat Synthesis of acyclo-C-nucleosides in the imidazo[1,2-a]pyridine and pyrimidine series as antiviral agents J. Med. Chem. 39 1996 2856 2859 (Pubitemid 26240354)